Similar articles

• Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide).

  FRIEDMAN AP, LOSIN S. FRIEDMAN AP, et al. Arch Neurol. 1961 Mar;4:241-5. doi: 10.1001/archneur.1961.00450090007002. Arch Neurol. 1961. PMID: 13701987 No abstract available.
• [First experiments in hemicrania and epilepsy with 1-methyl-lysergic acid butanolamide, a substance with antiserotonin effects].

  SICUTERI F. SICUTERI F. Prog Med (Napoli). 1960 Jan 15;16:20-2. Prog Med (Napoli). 1960. PMID: 14446409 Italian. No abstract available.
• Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine.

  SICUTERI F. SICUTERI F. Int Arch Allergy Appl Immunol. 1959;15:300-7. doi: 10.1159/000229055. Int Arch Allergy Appl Immunol. 1959. PMID: 14446408 No abstract available.
• History of methysergide in migraine.

  Koehler PJ, Tfelt-Hansen PC. Koehler PJ, et al. Cephalalgia. 2008 Nov;28(11):1126-35. doi: 10.1111/j.1468-2982.2008.01648.x. Epub 2008 Jul 15. Cephalalgia. 2008. PMID: 18644039 Review.
• Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent.

  Nichols DE, Monte A, Huang X, Marona-Lewicka D. Nichols DE, et al. Behav Brain Res. 1996;73(1-2):117-9. doi: 10.1016/0166-4328(96)00080-0. Behav Brain Res. 1996. PMID: 8788487 Review.